 |
217 Diseases |  |
230 Trials |
|
230 Trials |  |
3979 News |  |
| «12...3940414243444546474849...5051» |
- | tamoxifen / Generic mfg.
Trial completion: Tamoxifen in Treating Women With High-Risk Breast Cancer (clinicaltrials.gov) - Mar 20, 2016
P3, N=800, Completed, Sponsor: NCIC Clinical Trials Group
Active, not recruiting --> Completed
- |||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Combination therapy, Surgery, Metastases: PEONY: Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel (clinicaltrials.gov) - Mar 2, 2016
P3, N=328, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- epirubicin / Generic mfg.
Trial primary completion date: An Investigation of the Effect of the Promoter Polymorphism in the Glucuronosyltransferase 2B7 in Patients on Breast Cancer Treatment (clinicaltrials.gov) - Feb 29, 2016
P=N/A, N=120, Terminated, Sponsor: AHS Cancer Control Alberta
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2013 --> Dec 2005
- Erivedge (vismodegib) / Roche
New P2 trial: SHH-CM: Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients (clinicaltrials.gov) - Feb 29, 2016
P2, N=40, Not yet recruiting, Sponsor: Clinica Universidad de Navarra, Universidad de Navarra
- | Ingavirin (imidazolyl ethanamide pentandioic acid) / Myelo Therap, Valenta Pharm
New P2a trial: MyeloConcept: Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia (clinicaltrials.gov) - Feb 26, 2016
P2a, N=160, Recruiting, Sponsor: Myelo Therapeutics GmbH
- cisplatin / Generic mfg., paclitaxel / Generic mfg., epirubicin / Generic mfg.
Trial termination: Preoperative Dose-dense Chemotherapy With Weekly Cisplatin, Epirubicin and Paclitaxel to Treat Patients With Locally Gastric Cancer (clinicaltrials.gov) - Feb 24, 2016
P2, N=30, Terminated, Sponsor: Centre Hospitalier Universitaire de Besancon
Trial primary completion date: Jan 2013 --> Dec 2005 Active, not recruiting --> Terminated
- New trial: OTT15-04: Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC) (clinicaltrials.gov) - Feb 23, 2016
P=N/A, N=200, Not yet recruiting, Sponsor: Ottawa Hospital Research Institute
- ||||| Imfinzi (durvalumab) / AstraZeneca
New P2 trial, PD(L)-1 Biomarker, IO biomarker: GeparNuevo: Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer (clinicaltrials.gov) - Feb 18, 2016
P2, N=174, Not yet recruiting, Sponsor: German Breast Group
- |||| Avastin (bevacizumab) / Roche
Trial primary completion date: ST03: Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer (clinicaltrials.gov) - Feb 17, 2016
P2/3, N=1103, Recruiting, Sponsor: Professor David Cunningham
Active, not recruiting --> Terminated Trial primary completion date: Mar 2015 --> Mar 2016
- |||| Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Trial primary completion date: Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE) (clinicaltrials.gov) - Feb 16, 2016
P3, N=720, Completed, Sponsor: German Breast Group
Trial primary completion date: Mar 2015 --> Mar 2016 Trial primary completion date: Oct 2008 --> Sep 2006
- lapatinib / Generic mfg., epirubicin / Generic mfg.
Trial completion, Combination therapy, Metastases: Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30 (clinicaltrials.gov) - Feb 16, 2016
P1, N=10, Completed, Sponsor: ICORG- All Ireland Cooperative Oncology Research Group
Trial primary completion date: Oct 2008 --> Sep 2006 Active, not recruiting --> Completed
- || cyclophosphamide / Generic mfg., docetaxel / Generic mfg., epirubicin / Generic mfg.
New P3 trial: NNBC-3: 6 x FEC vs 3 x FEC Followed by Docetaxel in High-risk Node-negative Breast Cancer Patients (clinicaltrials.gov) - Feb 12, 2016
P3, N=4150, Completed, Sponsor: German Breast Group
- |||| albumin-bound paclitaxel / Generic mfg.
Trial primary completion date: GAIN-2: Study of Nab-Paclitaxel in High Risk Early Breast Cancer (clinicaltrials.gov) - Feb 10, 2016
P3, N=2886, Recruiting, Sponsor: German Breast Group
Active, not recruiting --> Completed Trial primary completion date: Jan 2016 --> Jan 2020
- | Trial completion, Trial primary completion date: Adjuvant Chemotherapy for Elderly Non Frail Patients With an Increased Risk for Relapse of a Primary Carcinoma of the Breast (clinicaltrials.gov) - Feb 10, 2016
P2/3, N=400, Completed, Sponsor: German Breast Group
Trial primary completion date: Jan 2016 --> Jan 2020 Active, not recruiting --> Completed | Trial primary completion date: Oct 2013 --> Jan 2014
- | Avastin (bevacizumab) / Roche
Trial completion: GeparQuinto: Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer (clinicaltrials.gov) - Feb 10, 2016
P3, N=2600, Completed, Sponsor: German Breast Group
Active, not recruiting --> Completed | Trial primary completion date: Oct 2013 --> Jan 2014 Active, not recruiting --> Completed
- Enrollment closed, BRCA Biomarker: BERNAQ: Randomized CT to Evaluate Efficacy of Neoadjuvant Chemotherapy Customized by Levels of BRCA1-HER2 Negative Breast Cancer (clinicaltrials.gov) - Feb 3, 2016
P2, N=30, Active, not recruiting, Sponsor: Fundaci
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Combination therapy, Metastases: BERENICE: A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer (clinicaltrials.gov) - Feb 2, 2016
P2, N=400, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2020 --> Nov 2020
- cyclophosphamide / Generic mfg., epirubicin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Trial primary completion date: Neonab: IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer (clinicaltrials.gov) - Jan 25, 2016
P2, N=60, Active, not recruiting, Sponsor: Barwon Health
Trial primary completion date: Aug 2020 --> Nov 2020 Trial primary completion date: Dec 2015 --> Jun 2016
- Trial primary completion date: Phase II Trial for Large ER-Negative Breast Cancers (clinicaltrials.gov) - Jan 20, 2016
P2, N=61, Active, not recruiting, Sponsor: University of Colorado, Denver
Trial primary completion date: Dec 2015 --> Jun 2016 Trial primary completion date: Dec 2014 --> Dec 2016
- | capecitabine / Generic mfg., docetaxel / Generic mfg., epirubicin / Generic mfg.
Enrollment change, HEOR, Metastases: BREAST-10: Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Jan 16, 2016
P3, N=139, Completed, Sponsor: National Cancer Institute, Naples
Trial primary completion date: Dec 2014 --> Dec 2016 N=280 --> 139
- |||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Combination therapy, Metastases: BERENICE: A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer (clinicaltrials.gov) - Jan 4, 2016
P2, N=400, Recruiting, Sponsor: Hoffmann-La Roche
N=280 --> 139 Active, not recruiting --> Recruiting
- metformin / Generic mfg.
Trial primary completion date: NeoMET Study in Neoadjuvant Treatment of Breast Cancer (clinicaltrials.gov) - Dec 30, 2015
P2, N=200, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
Active, not recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Dec 2017
- | carboplatin / Generic mfg., cyclophosphamide / Generic mfg., epirubicin / Generic mfg.
Enrollment open, Phase classification, Enrollment change, Trial primary completion date: TCTN: Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer (clinicaltrials.gov) - Dec 30, 2015
P3, N=970, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
Trial primary completion date: Dec 2016 --> Dec 2017 Not yet recruiting --> Recruiting | Phase classification: P2 --> P3 | N=300 --> 970 | Trial primary completion date: Jun 2018 --> Jun 2020
- cyclophosphamide / Generic mfg., docetaxel / Generic mfg., epirubicin / Generic mfg.
Trial completion: DIPE: Study of Danggui Buxue Decoction in Preventing Neutropenia (clinicaltrials.gov) - Dec 30, 2015
P2, N=50, Completed, Sponsor: Shanghai Jiao Tong University School of Medicine
Not yet recruiting --> Recruiting | Phase classification: P2 --> P3 | N=300 --> 970 | Trial primary completion date: Jun 2018 --> Jun 2020 Active, not recruiting --> Completed
- || New P2/3 trial: TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature (clinicaltrials.gov) - Dec 30, 2015
P2/3, N=503, Recruiting, Sponsor: Fudan University
- | New P1/2 trial, Combination therapy, Metastases: Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Dec 23, 2015
P1/2, N=60, Recruiting, Sponsor: Second Military Medical University
- cyclophosphamide / Generic mfg., paclitaxel / Generic mfg., epirubicin / Generic mfg.
Trial primary completion date: Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility (clinicaltrials.gov) - Dec 23, 2015
P=N/A, N=38, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Jun 2008 --> Jul 2005
- carboplatin / Generic mfg., paclitaxel / Generic mfg., epirubicin / Generic mfg.
Trial primary completion date, Combination therapy, Metastases: Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer (clinicaltrials.gov) - Dec 22, 2015
P4, N=120, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
Trial primary completion date: Jun 2008 --> Jul 2005 Trial primary completion date: Nov 2015 --> Nov 2016
- ||||| epirubicin / Generic mfg.
New P4 trial: Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation (clinicaltrials.gov) - Dec 16, 2015
P4, N=276, Not yet recruiting, Sponsor: Fudan University
- || Vyloy (zolbetuximab) / Astellas
Trial primary completion date, Combination therapy, Metastases: FAST: Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer (clinicaltrials.gov) - Dec 15, 2015
P2, N=210, Active, not recruiting, Sponsor: Ganymed Pharmaceuticals AG
Trial primary completion date: Nov 2015 --> Nov 2016 Trial primary completion date: Sep 2015 --> Sep 2018
- || epirubicin / Generic mfg.
New P3 trial: TACE Combined With Synchronous Radiofrequency /Microwave Ablation to Treat Large and Huge Hepatocellular Carcinoma (clinicaltrials.gov) - Dec 15, 2015
P3, N=280, Recruiting, Sponsor: Shanghai Zhongshan Hospital
- || vinorelbine tartrate / Generic mfg., paclitaxel / Generic mfg., epirubicin / Generic mfg.
Biomarker, New P3 trial, Metastases: Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations (clinicaltrials.gov) - Dec 11, 2015
P3, N=94, Recruiting, Sponsor: Fudan University
- | cyclophosphamide / Generic mfg., docetaxel / Generic mfg., epirubicin / Generic mfg.
New P4 trial, Surgery, Metastases: Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery (clinicaltrials.gov) - Dec 10, 2015
P4, N=200, Recruiting, Sponsor: Shandong University
- ||||| New P2 trial, PARP Biomarker: PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial (clinicaltrials.gov) - Dec 10, 2015
P2, N=200, Not yet recruiting, Sponsor: Haukeland University Hospital
- || carboplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
New P3 trial, Metastases: NeoTRIPaPDL1: Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1 (clinicaltrials.gov) - Dec 2, 2015
P3, N=272, Not yet recruiting, Sponsor: Fondazione Michelangelo
- GSK2302024A / GSK
Trial primary completion date: INDUCT: Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer (clinicaltrials.gov) - Nov 26, 2015
P2, N=60, Terminated, Sponsor: GlaxoSmithKline
Trial primary completion date: Sep 2015 --> Sep 2018 Trial primary completion date: Aug 2014 --> Nov 2014
- ||||| Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Enrollment change: KAITLIN: A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer (clinicaltrials.gov) - Nov 21, 2015
P3, N=1846, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Aug 2014 --> Nov 2014 Recruiting --> Active, not recruiting | N=2500 --> 1846
- carboplatin / Generic mfg., paclitaxel / Generic mfg., epirubicin / Generic mfg.
Trial primary completion date, Combination therapy, Metastases: Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer (clinicaltrials.gov) - Nov 5, 2015
P4, N=120, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
Recruiting --> Active, not recruiting | N=2500 --> 1846 Trial primary completion date: Jun 2015 --> Nov 2015
- ||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Combination therapy, Metastases: BERENICE: A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer (clinicaltrials.gov) - Nov 5, 2015
P2, N=401, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jun 2015 --> Nov 2015 Recruiting --> Active, not recruiting
- |||||||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P3 trial, Combination therapy, Surgery, Metastases: PEONY: Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel (clinicaltrials.gov) - Oct 26, 2015
P3, N=328, Not yet recruiting, Sponsor: Hoffmann-La Roche
- 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., epirubicin / Generic mfg.
Trial primary completion date, HEOR, Surgery: QUINTETT: Quality of Life in Neoadjuvant Versus Adjuvant Therapy of Esophageal Cancer Treatment Trial (clinicaltrials.gov) - Oct 22, 2015
P3, N=96, Recruiting, Sponsor: Richard Malthaner
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2012 --> Apr 2017
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Enrollment change, Trial termination, Trial primary completion date: PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer (clinicaltrials.gov) - Oct 22, 2015
P2, N=12, Terminated, Sponsor: The Methodist Hospital System
Trial primary completion date: Apr 2012 --> Apr 2017 N=100 --> 12 | Recruiting --> Terminated | Trial primary completion date: Aug 2016 --> Jun 2014; Funding agent withdrew funding
- Avastin (bevacizumab) / Roche
Enrollment change, Trial termination, Trial primary completion date, Combination therapy: Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer (clinicaltrials.gov) - Oct 22, 2015
P2, N=34, Terminated, Sponsor: Hellenic Oncology Research Group
N=100 --> 12 | Recruiting --> Terminated | Trial primary completion date: Aug 2016 --> Jun 2014; Funding agent withdrew funding N=48 --> 34 | Recruiting --> Terminated | Trial primary completion date: Oct 2014 --> Apr 2015; Due to poor accrual
- | Enrollment change, Trial initiation date, Trial primary completion date: POWERRANGER: Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma (clinicaltrials.gov) - Oct 5, 2015
P2/3, N=60, Recruiting, Sponsor: Gordon Buduhan
N=48 --> 34 | Recruiting --> Terminated | Trial primary completion date: Oct 2014 --> Apr 2015; Due to poor accrual N=12 --> 60 | Initiation date: Dec 2011 --> Sep 2015 | Trial primary completion date: Feb 2013 --> Feb 2017
- cyclophosphamide / Generic mfg., epirubicin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Trial primary completion date: Neonab: IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer (clinicaltrials.gov) - Sep 24, 2015
P2, N=60, Active, not recruiting, Sponsor: Barwon Health
N=12 --> 60 | Initiation date: Dec 2011 --> Sep 2015 | Trial primary completion date: Feb 2013 --> Feb 2017 Trial primary completion date: Jul 2015 --> Dec 2015
- | Tomudex (raltitrexed) / Pfizer, AstraZeneca
New P4 trial: Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases (clinicaltrials.gov) - Sep 23, 2015
P4, N=100, Recruiting, Sponsor: Zhu Xu
- | paclitaxel / Generic mfg., capecitabine / Generic mfg., epirubicin / Generic mfg.
Trial completion, Metastases: TEX trial: Epirubicin and Paclitaxel, Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer (clinicaltrials.gov) - Sep 17, 2015
P3, N=304, Completed, Sponsor: Thomas Hatschek
Trial primary completion date: Jul 2015 --> Dec 2015 Active, not recruiting --> Completed
- | cyclophosphamide / Generic mfg., docetaxel / Generic mfg., epirubicin / Generic mfg.
New P4 trial: ELEGANT: Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer (clinicaltrials.gov) - Sep 16, 2015
P4, N=264, Not yet recruiting, Sponsor: Ruijin Hospital
- | Vectibix (panitumumab) / Amgen
Enrollment open, Trial primary completion date: Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer (clinicaltrials.gov) - Sep 3, 2015
P2, N=40, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Recruiting | Trial primary completion date: Nov 2016 --> Nov 2017
- | cyclophosphamide / Generic mfg., docetaxel / Generic mfg., epirubicin / Generic mfg.
New P2 trial: The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer (clinicaltrials.gov) - Sep 2, 2015
P2, N=340, Not yet recruiting, Sponsor: First Affiliated Hospital Xi'an Jiaotong University